Related Experiment Videos
Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs
A L Christianson1, N Chesler, J G Kromberg
1Department of Paediatrics, University of the Witwatersrand, Johannesburg, South Africa.
Insights
Prenatal exposure to valproic acid can cause fetal valproate syndrome, leading to developmental delays and distinct facial features in children. This study highlights the spectrum of neurodevelopmental outcomes associated with in utero valproic acid exposure.
Area of Science:
- Neurodevelopmental Pediatrics
- Teratology
- Clinical Genetics
Background:
- Valproic acid is an anticonvulsant and mood-stabilizing medication.
- In utero exposure to valproic acid is a known risk factor for birth defects and developmental disorders.
- Fetal valproate syndrome is a recognized pattern of abnormalities associated with prenatal valproic acid exposure.
Observation:
- Four children from two sibling pairs with documented in utero exposure to valproic acid were assessed.
- Clinical and neurodevelopmental evaluations were performed, including assessments for developmental delay and dysmorphic features.
- Detailed case histories and physical examinations were conducted for each child.
Findings:
- Three of the four children exhibited global developmental delay, significant speech impairment, and dysmorphic features consistent with fetal valproate syndrome.
- One child presented with features of infantile autism in addition to global developmental delay.
- The fourth child had normal intellect but displayed a significant discrepancy between verbal and non-verbal abilities, along with some features of fetal valproate syndrome.
Implications:
- In utero valproic acid exposure can result in a spectrum of neurodevelopmental outcomes, ranging from severe global delay to specific learning disabilities.
- Early identification and intervention are crucial for children exposed to valproic acid prenatally.
- Further research is warranted to understand the full range of neurodevelopmental effects and to develop targeted support strategies.
Abstract:
The clinical and neurodevelopmental features are presented of four children--two sibling pairs--who were exposed in utero to valproic acid. One of each pair of children presented for diagnosis and assessment of developmental delay; the other sibling was examined at a later date. Three of the children were globally developmentally delayed with marked speech disability, and had dysmorphic features consistent with fetal valproate syndrome. One also had features of infantile autism. The fourth child had some of the dysmorphic features connected with fetal valproate syndrome, but had normal intellect, with his verbal ability being significantly below his non-verbal ability. He currently attends a school for learning-disabled children.